Price T Rowe Associates Inc Myriad Genetics Inc Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
A detailed history of Price T Rowe Associates Inc transactions in Myriad Genetics Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 53,568 shares of MYGN stock, worth $1.35 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
53,568
Previous 47,231
13.42%
Holding current value
$1.35 Million
Previous $905,000
26.3%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding MYGN
# of Institutions
191Shares Held
94.2MCall Options Held
280KPut Options Held
14.3K-
Black Rock Inc. New York, NY14.9MShares$376 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$253 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA8.06MShares$203 Million0.03% of portfolio
-
Camber Capital Management LP Boston, MA7.64MShares$193 Million3.99% of portfolio
-
State Street Corp Boston, MA5.4MShares$136 Million0.01% of portfolio
About MYRIAD GENETICS INC
- Ticker MYGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 80,634,800
- Market Cap $2.04B
- Description
- Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...